Peptide Therapy at Longevity Clinics: FDA Status and Safety Questions (2026)

As of August 28, 2026, the FDA has not approved BPC-157, KPV, TB-500, MOTS-c, emideltide, Semax, or Epitalon for longevity treatment. A federal advisory meeting held on July 23 and 24 considered whether bulk forms of those substances should be included on the section 503A compounding list. Discussion by an advisory committee is not drug approval, and its recommendations are not legally binding on the FDA.

That distinction matters because longevity clinics often blur three different questions:

1. Is a substance an FDA-approved drug for a specific indication?
2. May a pharmacy compound a preparation from that bulk substance under section 503A?
3. Is there reliable evidence that the proposed treatment benefits this patient?

A positive answer to one does not establish the other two.

This guide covers United States federal regulation. Other countries have different rules, and state pharmacy and medical-practice requirements may add further restrictions.

Why this was described as a peptide reclassification

In February 2026, HHS Secretary Robert F. Kennedy Jr. said federal policy toward some compounded peptides would change. NPR reported the announcement and the competing safety and access arguments around it.

The announcement was a policy signal, not a final FDA action approving a named list of peptides or making every compounded formulation legal. The later official record must be checked substance by substance. That is why this guide uses the July meeting record, section 503A materials, and FDA safety pages rather than treating the announcement as the current legal status.

What the July 2026 FDA meeting covered

The official FDA meeting record identifies seven groups of bulk drug substances and the uses the agency evaluated:

Bulk substance discussed	Use evaluated by FDA
BPC-157 free base and acetate	Ulcerative colitis
KPV free base and acetate	Wound healing and inflammatory conditions
TB-500 free base and acetate	Wound healing
MOTS-c free base and acetate	Obesity and osteoporosis
Emideltide, also called DSIP	Opioid withdrawal, chronic insomnia, and narcolepsy
Semax free base and acetate	Cerebral ischemia, migraine, and trigeminal neuralgia
Epitalon free base and acetate	Insomnia

These are the nominated uses reviewed for the compounding-list process. They are not endorsements of the substances, approvals for those uses, or evidence for broad claims about recovery, anti-aging, cognition, body composition, or lifespan.

The FDA page includes briefing documents and presentations but does not publish a final rule adding these substances to the 503A bulks list. The agency explains that advisory committees provide non-binding expert recommendations. A clinic should therefore be able to identify the later FDA action it relies on, not merely point to the meeting.

What section 503A actually says

The FDA’s section 503A overview says that a state-licensed physician or pharmacist may compound from a bulk substance only when the substance meets one of the relevant statutory routes. In simplified terms, the substance must:

• comply with an applicable USP or National Formulary monograph, if one exists;
• be a component of an FDA-approved drug when no applicable monograph exists; or
• appear on the FDA’s 503A bulks list when neither of the first two routes applies.

The bulk substance must also have a valid certificate of analysis and come from an FDA-registered manufacturing establishment.

FDA’s interim policy historically grouped nominated substances into three categories. Category 1 could receive enforcement discretion if the guidance conditions were met. Category 2 identified potential significant safety risks and did not receive that policy. Category 3 lacked enough nomination information for evaluation. FDA also states that nominations made on or after January 7, 2025 are no longer placed into those interim categories.

This is more precise than saying a peptide is simply “legal,” “banned,” or in a “gray market.” The relevant substance, formulation, route, pharmacy, prescriber, indication, date, and enforcement policy all matter.

Safety signals in FDA materials

The FDA’s page on bulk substances that may present significant safety risks explains why evidence should not be inferred from clinic availability.

For the substances discussed in July, the agency records concerns including:

• BPC-157: possible immunogenicity, peptide-related impurities, difficult active-ingredient characterization, and limited safety information for proposed routes;
• KPV: no human exposure data identified by FDA for drug products using the proposed routes;
• TB-500: no human exposure data identified and limited information about potential harm;
• MOTS-c: no human exposure data identified, with uncertainty about immunogenicity and impurities;
• Emideltide: no safety information identified for the proposed route;
• Semax: no or limited safety information for proposed routes;
• Epitalon: no safety information identified for the proposed route, with potential immunogenicity and impurity concerns.

“No human exposure data identified” does not prove that a substance is harmful. It means a clinic cannot responsibly present safety as established.

Evidence and regulation are separate tests

Many peptide claims begin with cell or animal research. That work can justify further study, but it does not establish a clinical dose, manufacturing standard, long-term safety profile, or patient benefit.

Ask what kind of evidence supports the exact claim:

• cell or animal experiment;
• uncontrolled human case series;
• randomized human trial;
• approved indication and prescribing information;
• professional guideline or regulator decision.

A compounder’s ability to prepare a product does not make the product FDA-approved. “Research grade” is not a patient-safety standard or a lawful shortcut for selling an unapproved drug for human use. Off-label prescribing, where legally permitted, applies to an approved drug used outside its approved labeling; it should not be used as a blanket explanation for an unapproved bulk substance.

Questions to ask a clinic before paying

Do not start with price. Ask for written answers to these questions:

1. What is the exact active ingredient, salt or acetate form, route, dose, and intended indication?
2. Is the product FDA-approved? If so, what is the approved product and indication?
3. If compounded, which pharmacy prepares it and which section of federal law does the clinic rely on?
4. Can the clinic provide the pharmacy name, lot information, certificate of analysis, sterility testing, and storage instructions?
5. What human evidence supports this use, not merely the molecule’s proposed mechanism?
6. What adverse effects, interactions, contraindications, and stopping rules apply?
7. Which licensed clinician evaluates the indication and monitors treatment?
8. How are adverse events documented and reported?
9. What conventional or approved alternative is available?
10. Has the legal status changed since the July meeting, and where is the current FDA action published?

Walk away if a clinic cannot name the pharmacy, treats a PCAC discussion as FDA approval, guarantees repair or age reversal, or dismisses manufacturing and sterility questions as technicalities.

Bottom line

The July 2026 meeting created a public evidence record for seven groups of bulk substances. It did not establish that they work for longevity, did not make clinic protocols FDA-approved, and did not remove the need to verify compounding status and patient-specific risk.

The safest buying rule is simple: require a current regulatory basis, human evidence for the exact use, traceable manufacturing, a licensed prescriber, and a monitoring plan. If the sales claim is clearer than the legal and clinical explanation, do not buy the protocol.

This article is informational and does not provide medical or legal advice. Discuss any proposed peptide treatment with a qualified clinician and verify current regulation with the FDA, the relevant state board, and the dispensing pharmacy.